Vor Biopharma Inc. $VOR Shares Acquired by UBS Group AG

UBS Group AG lifted its stake in shares of Vor Biopharma Inc. (NASDAQ:VOR) by 284.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 292,118 shares of the company’s stock after purchasing an additional 216,209 shares during the quarter. UBS Group AG owned about 2.81% of Vor Biopharma worth $3,821,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Goldman Sachs Group Inc. increased its position in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the period. Jane Street Group LLC acquired a new stake in Vor Biopharma in the 1st quarter valued at approximately $140,000. XTX Topco Ltd acquired a new stake in Vor Biopharma in the 2nd quarter valued at approximately $66,000. BNP Paribas Financial Markets increased its position in Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after acquiring an additional 5,058 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Vor Biopharma in the 3rd quarter valued at approximately $230,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on VOR. HC Wainwright restated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Wedbush raised their target price on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Finally, Wells Fargo & Company began coverage on Vor Biopharma in a research report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Vor Biopharma Trading Down 4.7%

Shares of VOR stock opened at $14.33 on Friday. Vor Biopharma Inc. has a 1 year low of $3.30 and a 1 year high of $65.80. The business’s fifty day moving average is $15.05 and its 200-day moving average is $13.83.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock in a transaction on Monday, April 6th. The stock was sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the transaction, the director directly owned 4,555,741 shares in the company, valued at approximately $75,579,743.19. This trade represents a 11.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 3,002,903 shares of company stock worth $49,412,176. 0.45% of the stock is currently owned by company insiders.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).